REVOLUTION MEDICINES Aktie

 

Revolution Medicines Inc. secured US regulatory approval for its pancreatic cancer drug daraxonrasib, the first medicine to target one of the key molecular causes of the disease....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

One of the most successful investors ever really likes this up-and-coming biotech stock....

Der Onkologie-Spezialist Revolution Medicines gehört zu den Überfliegern der Biotech-Szene 2026. Auf Jahressicht hat die Aktie satte 487 Prozent zugelegt. Zwischenzeitliche Übernahmegerüchte und bahnbrechende Studienergebnisse im Kampf gegen Bauchspeicheldrüsenkrebs sorgten für diese unglaubliche Neubewertung....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Biotech advances RAS-inhibitor pipeline with $3.9B cash and FDA acceptance of daraxonrasib NDA....

RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math on who can actually write the check gets complicated fast....

The deal includes joint studies combining BeOne's cancer pipeline assets with four clinical-stage RAS(ON) inhibitors from Revolution Medicines, alongside a regional rights agreement for select Asian markets. The The post BeOne and Revolution Medicines partner for oncology therapies appeared first on Pharmaceutical Business review....

BEONE MEDICINES (06160.HK) announced that it has entered into a multifaceted collaboration agreement with oncology therapeutics company Revolution Medicines, Inc. (RVMD.US), covering both clinical development collaboration and regional licensing.The two parties will jointly evaluate combination treatment regimens involving certa......

Revolution Medicines posts a wider-than-expected loss in Q2 and raises its 2026 expense outlook again as investors weigh higher spending and pipeline progress....

Die Biotech-Gesellschaft hat im Frühjahr mit einem Spätphasen-Erfolg zur Behandlung von zuvor therapiertem Bauchspeicheldrüsenkrebs für Furore gesorgt. Noch verfügt der Hoffnungsträger über keine offizielle Zulassung – doch das sollte sich bald ändern....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

REDWOOD CITY, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2026, and provided an update on corporate progress....

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress....

Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer....

Die Biotech-Gesellschaft Revolution Medicines hat vor wenigen Monaten einen Durchbruch bei der Behandlung von Bauchspeicheldrüsenkrebs verbuchen können. In den USA und der EU laufen bereits die Zulassungsprozesse für den Gamechanger Daraxonrasib, der schon bald den Betroffenen in Übersee zur Verfügung stehen könnte....

Revolution Medicines could be a revolutionary biotech stock....

Erasca's repeated preclinical comparisons to Revolution Medicines' RMC-6236 were allegedly improper and placed the company at risk of patent and trade secret violations, costing investors over $11 per share when the truth emerged. NEW YORK, July 16, 2026 /PRNewswire/ -- SueWallSt notifies......

SAN FRANCISCO, July 14, 2026 /PRNewswire/ -- Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca of patent infringement concerning Erasca's pan-RAS molecular glue targeting solid tumors......